Free Trial
NASDAQ:SCLXW

Scilex (SCLXW) Stock Price, News & Analysis

Scilex logo
$0.10 0.00 (-0.30%)
As of 06/17/2025 01:45 PM Eastern

About Scilex Stock (NASDAQ:SCLXW)

Key Stats

Today's Range
$0.10
$0.10
50-Day Range
$0.05
$0.13
52-Week Range
$0.04
$0.53
Volume
881 shs
Average Volume
7,419 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Scilex Holding Company focuses on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Its commercial products include ZTlido (lidocaine topical system) 1.8% (ZTlido), a prescription lidocaine topical product for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a ready-to-use oral solution for the acute treatment of migraine with or without aura in adults; and GLOPERBA, a liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults. The company is also developing three product candidates, including SP-102 (10 mg dexamethasone sodium phosphate viscous gel) (SEMDEXA), a novel viscous gel formulation of a used corticosteroid for epidural injections, which has completed a Phase 3 study to treat lumbosacral radicular pain or sciatica; SP-103 (lidocaine topical system) 5.4% (SP-103), a formulation of ZTlido for the treatment of chronic neck pain and low back pain (LBP) that has completed a Phase 2 trial; and SP-104 (4.5 mg low-dose naltrexone hydrochloride delayed-release capsules) (SP-104), a novel low-dose delayed-release naltrexone hydrochloride, which has completed Phase 1 trials for the treatment of fibromyalgia. The company is headquartered in Palo Alto, California.

Receive SCLXW Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Scilex and its competitors with MarketBeat's FREE daily newsletter.

SCLXW Stock News Headlines

Why Wall Street Is Quietly Loading Up Ahead of Tesla’s Austin Breakout
In the next few days, Elon Musk could trigger the biggest wealth shift in a generation. And two of Wall Street’s sharpest minds – Cathie Wood and Dan Ives – are already positioning themselves ahead of the announcement. Why? Because what’s about to launch in Austin isn’t just a new product… It’s the starting gun for a $34 trillion wealth event tied to autonomous vehicles, AI, and Musk’s newest innovation.
Scilex announces approval of NDS from Health Canada for ELYXYB
See More Headlines

SCLXW Stock Analysis - Frequently Asked Questions

Scilex's stock was trading at $0.21 at the beginning of 2025. Since then, SCLXW shares have decreased by 52.5% and is now trading at $0.0997.
View the best growth stocks for 2025 here
.

Shares of SCLXW stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Drug Manufacturers - General
Sub-Industry
N/A
Current Symbol
NASDAQ:SCLXW
Fax
N/A
Employees
105
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$50.71 million
Price / Cash Flow
N/A
Price / Book
N/A

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
N/A
Options Trading Made Easy - Download Now Cover

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

This page (NASDAQ:SCLXW) was last updated on 6/18/2025 by MarketBeat.com Staff
From Our Partners